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 Summary 
 The present report summarizes the most current information available to the 
United Nations Office on Drugs and Crime on the illicit demand for drugs 
throughout the world and the promotion of rehabilitation- and reintegration-oriented 
strategies in response to drug use disorders and their consequences. It has been 
prepared pursuant to the international drug control conventions, as well as 
Commission on Narcotic Drugs resolutions 53/16 and 54/5. Compared with the 
estimates for 2008, there does not appear to have been a significant change in the 
prevalence and number of people using illicit drugs in 2009. Worldwide, it is 
estimated that between 3.4 and 6.2 per cent of people aged 15-64 years, or between 
149 million and 272 million people, had used an illicit drug at least once in the 
preceding year. Global emerging trends are outlined in section I, which provides 
context with regard to drug use. Section II provides regional summaries. Section III 
provides an overview of efforts made by Member States to promote rehabilitation- 
and reintegration-oriented strategies in response to drug use disorders and their 
consequences. Section IV includes conclusions and recommendations. 
 
 
__________________ 
 * E/CN.7/2012/1. 
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 I. Emerging global trends 
 
 
1. The present report contains a summary of the most up-to-date information 
available to the United Nations Office on Drugs and Crime (UNODC) on illicit 
demand for drugs worldwide, as reported by Member States through the annual 
report questionnaire and other existing sources. New trends observed in the past 
year include the following: 
 • There are stabilizing or decreasing trends in the use of traditional drugs of 
abuse such as heroin and cocaine. This is especially evident in Europe and 
North America. 
 • These are signs of increasing use of cocaine in Africa and Asia. 
 • Cannabis use is decreasing in Europe, but there is a resurgence of its use 
among young people in North America, Africa and Asia. 
 • The use of amphetamine-type stimulants is increasing, mainly in Asia and 
South America. 
 • After some years of decline, there is also a resurgence of “ecstasy” use, 
primarily in Europe and South America. 
 • The non-medical use of synthetic and prescription opioids and prescription 
stimulants is a growing concern, especially in North America, Europe and 
Oceania. 
 • The introduction of newer synthetic substances — the so-called “legal highs”, 
such as the bath salts and synthetic cannabinoids sold under the brand name 
“Spice”, that are manufactured using precursors that are not under 
international control and that mimic the effects of controlled drugs, is posing 
public health concerns. 
2. In 2009 one injecting drug user in every five was living with HIV, while nearly 
half of all injecting drug users were reportedly infected with hepatitis C virus. It is 
estimated that between 104,000 and 263,000 deaths throughout the world could be 
attributed to drug use; most of the deaths that could have been prevented were fatal 
overdose cases and occurred among opioid users. The abuse of amphetamine-type 
stimulants is increasing, noticeably in Latin America and Asia, with 
methamphetamine abuse increasing in parts of East and South-East Asia and 
amphetamine abuse on the rise in the Near and Middle East. The non-medical use of 
synthetic and prescription opioids, benzodiazepines and prescription stimulants is a 
growing concern. Similarly, the introduction of newer synthetic substances 
manufactured using precursors not under international control poses additional 
public health challenges. There remains a major gap in the delivery of evidence-
based treatment and care for drug dependence in most regions, with only between 
12 and 30 per cent of estimated problem drug users being provided treatment  
in 2009. There continues to be a lack of objective and current information on most 
epidemiological indicators of drug use, as well as an overall low response rate to the 
annual report questionnaire. The non-existence of sustainable drug information 
systems and drug observatories continues to hinder the monitoring of current and 
emerging drug trends in most regions, as well as the implementation and evaluation 
of evidence-based responses to counter the demand for drugs. 
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3. The revised annual report questionnaire was endorsed by the Commission on 
Narcotic Drugs at its reconvened fifty-fourth session, with the aim and expectation 
of improving both the response rate and the quality of the information on the drug 
abuse situation reported by Member States. Out of the 192 Member States and  
15 territories that were sent the annual report questionnaire, 82 had submitted their 
responses to the part of the annual report questionnaire on the extent and patterns of 
and trends in drug use (part three of the questionnaire) by November 2011, a 
response rate of nearly 40 per cent. Of these, 60 per cent of the responses submitted 
included substantial information; that is, they contained replies to at least half of the 
main questions, while more than one third of them were merely filled in with some 
information. There has been a lack of reporting from many parts of Africa, Asia and 
the Pacific, some parts of Latin America and from countries with major drug 
problems (see map 1). As the rate of response to the annual report questionnaire has 
been dwindling over the years, an attempt is being made to complement the 
information obtained through the questionnaire with information from other national 
and regional sources and scientific literature. 
  
E/CN.7/2012/2 
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 A. Understanding the context of illicit drug use  
 
 
4. For a comprehensive understanding of the situation, it is imperative to look at 
the different dimensions of the phenomenon of illicit drug use. This includes 
understanding the extent of illicit drug use among the general population; the extent 
of drug use disorders, drug dependence and problem drug use; and the health 
consequences of drug use, as reflected in demand for treatment and information on 
drug-related morbidity (e.g. HIV and other blood-borne infections) and mortality 
among illicit drug users. An attempt has been made to provide information on these 
aspects in the present report. 
 
 
 B. Extent of drug use  
 
 
5. Drug use surveys conducted among the general population, as well as among 
youth, provide an objective assessment of the extent and nature of drug use in a 
particular country. Given the scope of the surveys, all but three countries1 that 
conduct population-based surveys on drug use repeat them only once every  
3-5 years. Many developing countries have never conducted a population-based 
survey on drug use, however, and rely mainly on the information gathered through 
registered drug users2 or rapid assessments in an attempt to understand their drug 
use situation. 
 
 
__________________ 
 1  Canada, the United Kingdom of Great Britain and Northern Ireland and the United States of 
America. 
 2  These may include those registered by health services or law enforcement authorities as a result 
of administrative or punitive measures relating to drug use. 
E/CN.7/2012/2 
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6. In 2009, between 3.4 and 6.2 per cent of people aged 15-64 years, 
corresponding to between 149 million and 272 million people, were estimated to 
have used an illicit drug at least once during the prior year. These estimates have not 
changed significantly from previous years. The range of drug users includes 
experimental or occasional drug users, as well as a smaller yet significant number of 
dependent or problem drug users.  
Figure I 
  Annual prevalence of illicit drug use, from the late 1990s to 2009/10 
 
 
  Source: World Drug Report 2011 (United Nations publication, Sales No. E.11.XI.10). 
7. Cannabis remains the most widely used controlled substance in the world, the 
number of cannabis users being estimated at between 125 million and 203 million 
(2.8 to 4.5 per cent of the population aged 15-64). Oceania (primarily Australia and 
New Zealand), North America and Western and Central Europe remain the regions 
with the highest prevalence of cannabis use. Contrary to the previously held view of 
cannabis being a substance that does not cause much harm, cannabis users are 
increasingly being reported as seeking treatment for their drug use disorders and for 
associated psychiatric morbidity. 
8. Amphetamine-type stimulants are the second most widely used drugs 
worldwide, outstripping heroin or cocaine. In 2009, there were between 13.7 million 
and 56.4 million past-year users (0.3-1.3 per cent of the population aged 15-64 years) 
of amphetamine-group substances and between 11 million and 28 million users  
(0.2-0.6 per cent) of “ecstasy”-group substances. The type of amphetamine-group 
substance used in different regions varies considerably. In East and South-East Asia 
and Oceania, methamphetamine is the primary substance used. Tablets containing 
amphetamine and sold as Captagon are used throughout the Near and Middle East. 
In Europe, users of amphetamine-group substances primarily consume amphetamine 
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(although there are signs that methamphetamine may be replacing amphetamine in 
some parts of Europe), whereas stimulant users in North America typically use 
methamphetamine and prescription stimulants. In Africa, use of amphetamine-group 
substances may comprise mainly the use of prescription stimulants.  
Figure II 
  Annual prevalence of drug use globally 
 
  Source: World Drug Report 2011 (United Nations publication, Sales No. E.11.XI.10). 
9. “Ecstasy”-group substances primarily include methylenedioxymethamphetamine 
(MDMA) and its analogues, and their use is often associated with recreational and 
entertainment settings such as nightclubs and raves. The prevalence of their abuse is 
therefore particularly high among young people in affluent societies, with the 
highest prevalence rate reported in Oceania, North America and Europe. In previous 
years, many European countries reported a declining availability of “ecstasy”; 
however, most recent reports indicate a possible resurgence and increasing purity of 
“ecstasy” available in Europe.3  
10. It is estimated that worldwide there are between 24.6 million and 36.8 million 
opioid users who had used any of the opioids at least once in the past year  
(0.5-0.8 per cent of those aged 15-64 years). While heroin use has stabilized at high 
prevalence levels as the most commonly used opioid, the use of opioids has evolved 
differently in many countries. In North America, South America and Oceania  
(New Zealand and Australia in particular), the abuse or misuse of prescription 
opioids now constitutes the main problem, whereas the use of heroin is limited. In 
Europe, heroin is the main opioid used, with misuse of prescription opioids reported 
in some countries, although the extent of misuse of prescription opioids in Europe 
__________________ 
 3  Amphetamines and Ecstasy: 2011 Global Amphetamine-type Stimulants Assessment (United 
Nations publication, Sales No. E.11.XI.13). 
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needs to be further investigated. In Eastern Europe and to some extent in South-
Eastern Europe, in addition to the use of heroin, the use of locally made 
preparations such as kompot,4 cherniashka5 or krokodil6 is also common. In the 
countries with a tradition of opium poppy cultivation and in some of their 
neighbouring countries, in particular Afghanistan, Iran (Islamic Republic of), the 
Lao People’s Democratic Republic and Myanmar, the common practice is to use 
opium rather than heroin. Heroin is the main opioid used in Africa and Asia, but 
there are also reports indicating the misuse of prescription opioids being a common 
practice. Opioids remain by far the drug type that has caused the most harm in terms 
of increasing treatment demand and HIV and other infections, as well as a major 
cause of overdose and death among drug abusers. 
11. In 2009, it was estimated that between 14.3 million and 20.5 million adults 
(people aged 15-64 years) were reported to have used cocaine at least once in the 
previous year, corresponding to 0.3-0.5 per cent of the world’s adult population. 
Most indicators (e.g. treatment demand, emergency room visits and overdose cases) 
suggest that cocaine is the second most problematic drug worldwide. Although the 
prevalence of cocaine use remains high, there are stable trends in most parts of the 
established cocaine markets in Central America, South America and Europe, and 
decreasing trends in North America. On the other hand, the situation is different in 
parts of Asia, the Middle East and West Africa: the increasing seizures of cocaine 
being reported in those areas indicate that cocaine use may surge in places where its 
use has remained low or uncommon.  
12. Although global figures on the non-medical use of prescription drugs other 
than opioids and amphetamines are not available, the use of such drugs, including 
tranquillizers and sedatives, is reportedly a growing health problem, with prevalence 
rates for such drugs higher than the rates for many of the controlled drugs in some 
countries. Non-medical use of prescription drugs is reported to be common among 
young adults, women, elderly patients and health-care professionals. Another major 
concern is that the growing number of polydrug users among illicit drug users either 
use prescription drugs in combination with their illicit drug of choice to enhance the 
effects or substitute their illicit drug of choice with prescription drugs in cases of 
temporary disruption of its supply. 
13. “Legal highs”, or synthetic substances that are chemically engineered to 
remain outside international controls, are also increasingly being identified and used 
in Europe and other parts of the world. The most notable of these substances include 
the methcathinone analogue 4-methyl-methcathinone (also known as “mephedrone”) 
and methylenedioxypyrovalerone (MDPV), which are often sold as “bath salts” or 
“plant food” and act as substitutes for controlled stimulant drugs such as cocaine or 
“ecstasy”. Similarly, piperazine derivatives such as N-benzylpiperazine (BZP) and 
1-(3-trifluoromethylphenyl)piperazine (TFMPP) are also sold as substitutes for 
“ecstasy”. Several synthetic cannabinoids (sold under brand names such as Spice) 
that emulate the effect of cannabis but contain products that are not under 
international control, have also been detected since 2008 in herbal smoking blends.7 
Other synthetic substances that are not under international control and that are being 
__________________ 
 4  A crude preparation made from poppy straw and injected. 
 5  Produced by mixing locally grown poppy with acetic anhydride. 
 6  Made from codeine, iodine and red phosphorus. 
 7  World Drug Report 2011 (United Nations publication, Sales No. E.11.XI.10). 
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used to mimic effects of controlled drugs or as substitutes have also been reported, 
mainly in Europe and North America but also in other regions. These substances 
include indanes, benzodifuranyls, narcotic analgesics (such as codeine for 
conversion into krokodil, or desomorphine, in the Russian Federation), synthetic 
cocaine derivatives, ketamine (a substance commonly found in South-East Asia) and 
phencyclidine derivatives.8 
 
 
 C. Consequences of drug use  
 
 
  Problem drug use 
 
14. The extent of problem drug use, such as injecting drug use, and estimates of 
the number of drug-dependent persons or regular drug users are important indicators 
to determine the costs and consequences of drug use. In 2009, it is estimated that 
between 15 million and 39 million people, or 0.3 to 0.9 per cent of the adult 
population aged 15-64, were problem drug users. A high proportion of them were 
opioid and/or cocaine users. Furthermore, it is estimated that 16 million people 
worldwide (the range is from 11 million to 21 million) inject drugs.9 It is estimated 
that more than a quarter of injecting drug users are in Western and Eastern Europe 
and South, East and South-East Asia. The main substances reported to be injected 
are opioids, especially heroin; amphetamine-type stimulants such as 
methamphetamine; and “crack” cocaine. 
 
  Treatment demand 
 
15. Treatment demand is another indicator of problem drug use that also indicates 
the type of substances causing particular problems in a country or region. 
Notwithstanding the extent of coverage and availability of services providing 
treatment and care for drug dependence, as many as 4.7 million people worldwide 
were provided treatment for drug use disorders in 2009. This constitutes between  
12 and 30 per cent of the estimated problem drug users in the world, indicating a 
major gap in service delivery and an unmet need for treatment and care among drug 
users. In most regions, the main problematic drugs can be identified. In Europe and 
Asia, opioids remain the main problematic drugs (see map 2). In some Asian 
countries, amphetamine-type stimulants, such as methamphetamine in South-East 
Asia and tablets containing amphetamine and sold as Captagon in the Middle East, 
are the predominant problematic drugs reported in treatment settings. Demand for 
treatment for dependence on amphetamine-type stimulants is also noticeable in 
Oceania (particularly Australia and New Zealand), North America and Western and 
Central Europe. In South America, cocaine is the primary drug in the largest number 
(50 per cent) of cases reported for treatment. In Africa, treatment demand for 
cannabis-related disorders is reported at an even higher rate (60 per cent of all 
treatment provided in 2009), as is the case in Oceania, North America and South 
America.  
 
__________________ 
 8  The State of the Drugs Problem in Europe: Annual Report 2011 (European Monitoring Centre 
for Drugs and Drug Addiction, November 2011). 
 9  Reference Group to the United Nations on HIV and Injecting Drug Use (2008 estimates). 
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  HIV and other infections 
 
16. Risky injecting and sexual behaviour among drug users become major public 
health concerns owing to the high risk of infection with HIV and hepatitis B and C 
viruses. This is particularly the case among marginalized and the most at risk 
populations. In 2010 an estimated 34 million people were living with HIV 
worldwide; among the estimated 16 million people who inject drugs, around  
3 million, or approximately one fifth, were living with HIV. With the exception of 
sub-Saharan Africa, injecting drug use accounted for about a third of all new  
HIV infections reported for 2010.10 While use of contaminated needles and syringes 
among injecting drug users has been the major cause of HIV infections, several 
studies have indicated that the use of cocaine, “crack” cocaine and amphetamine-
type stimulants by non-injection routes of administration is also associated with 
increased risks of HIV infection, in particular through unprotected sex.11  
17. The prevalence of hepatitis C virus infection among injecting drug users 
worldwide is also quite high, with half of estimated injecting drug users reported to 
be infected with the virus. Of the 51 countries that reported the prevalence of 
hepatitis C infection in 2009, 13 reported rates of over 70 per cent among injecting 
drug users. Similarly, 22 per cent of injecting drug users were estimated to be 
infected with hepatitis B virus. This translates into an estimated 3.5 million 
injecting drug users infected with hepatitis B. 
 
  Drug-related mortality 
 
18. Deaths related to or associated with illicit drug use may include fatal 
overdoses, suicides, accidents while under the influence of drugs, deaths among 
injecting drug users from infections such as HIV or AIDS and deaths resulting from 
medical conditions associated with long-term drug use. According to data compiled 
by UNODC, there were between 104,000 and 263,000 drug-related deaths in 2009, 
or between 23.1 and 58.7 deaths per million population aged 15-64, that were 
attributed to drug use. Nearly half of the reported deaths were attributed to fatal 
overdoses. In Africa, Asia, Europe and Oceania, opioids are ranked as the main drug 
type associated with drug-related deaths, while in the Americas it is cocaine. 
Inconsistencies in recording drug-related deaths, as well as the underreporting of 
such deaths in many regions, pose challenges to estimating their true extent. 
  
__________________ 
 10  Joint United Nations Programme on HIV/AIDS (UNAIDS), World AIDS Day Report 2011 
(Geneva, 2011). 
 11  G. Colfax and others, “Amphetamine-group substances and HIV”, The Lancet, vol. 376,  
No. 9739 (7 August 2010). 
E/CN.7/2012/2
13V.12-50070 
 
M
ap
 3
 
 
 
D
ru
g-
re
la
te
d 
de
at
hs
, 2
00
9 
 
 
 
 N
ot
e:
 T
he
 b
ou
nd
ar
ie
s 
an
d 
na
m
es
 s
ho
w
n 
an
d 
th
e 
de
si
gn
at
io
ns
 u
se
d 
on
 th
is
 m
ap
 d
o 
no
t i
m
pl
y 
of
fi
ci
al
 e
nd
or
se
m
en
t o
r 
ac
ce
pt
an
ce
 
by
 th
e 
U
ni
te
d 
N
at
io
ns
. 
 
 D
ot
te
d 
lin
e 
re
pr
es
en
ts
 a
pp
ro
xi
m
at
el
y 
th
e 
Li
ne
 o
f 
C
on
tr
ol
 in
 J
am
m
u 
an
d 
K
as
hm
ir
 a
gr
ee
d 
up
on
 b
y 
In
di
a 
an
d 
Pa
ki
st
an
. T
he
 f
in
al
 
st
at
us
 o
f 
Ja
m
m
u 
an
d 
K
as
hm
ir
 h
as
 n
ot
 y
et
 b
ee
n 
ag
re
ed
 u
po
n 
by
 th
e 
pa
rt
ie
s.
 
   
 14 V.12-50070 
 
E/CN.7/2012/2  
 D. Perception of drug use  
 
 
19. Along with the statistics on drug use and harm, expert perceptions of changes 
in drug use can provide useful qualitative information on regional and global trends. 
Since such perceptions might not always rely on objective data, they should be 
interpreted with caution. In 2010, out of the 82 Member States and territories that 
responded to the annual report questionnaire, nearly half reported expert perceptions 
of drug use trends. As can be seen in figure III, there has been a consistent decline 
since 2007 in the number of Member States submitting the annual report 
questionnaire and in the number providing expert perceptions of drug use trends.  
Figure III 
  Number of Member States providing expert perception data, by drug group,  
2000-2010 
 
 
  Source: United Nations Office on Drugs and Crime, annual report questionnaire. 
20. Overall, there are generally stable trends reported in the use of cocaine and 
opioids globally, while a higher proportion of countries perceive the use of cannabis 
and amphetamine-type stimulants to be increasing. This is especially the case in 
Africa for cannabis, in Asia for cannabis and amphetamine-type stimulants and in 
Latin America for amphetamine-type stimulants and opioids.  
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Figure IV 
  Number of countries reporting a perceived increase, decrease or stability in 
cocaine use, 2000-2010 
(As at 14 December) 
 
 
 
 
Figure V 
  Number of countries reporting a perceived increase, decrease or stability in 
opioid use, 2000-2010 
(As at 14 December) 
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Figure VI 
  Number of countries reporting a perceived increase, decrease or stability in the 
use of amphetamine-type stimulants, 2000-2010 
(As at 14 December) 
 
 
 
 
 
 
Figure VII 
  Number of countries reporting a perceived increase, decrease or stability in 
cannabis use, 2000-2010 
(As at 14 December) 
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 II. Regional summaries 
 
 
 A. Africa  
 
 
21. For 2010 most of the Member States in Africa reported an increasing trend in 
the use of cannabis and opioids and stable trends for cocaine and amphetamine-type 
stimulants. Nigeria is among those countries that reported a gradual increase in the 
number of heroin users compared with previous years.12  
22. Cannabis is the most commonly used controlled substance in Africa, which is 
also reflected in treatment demand; 64 per cent of all treatment provided is 
reportedly for disorders related to cannabis use.  
Figure VIII 
  Distribution of primary drug of abuse among people entering treatment in 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Source: World Drug Report 2011. 
   Note: Owing to variations in reporting methods, figures do not add up to 100. 
23. In West Africa, it is speculated that the increasing trafficking of cocaine 
through the coastal countries is leading to an increase in cocaine13 use, with cocaine 
being more frequently used than heroin. A survey conducted among secondary 
school students in Freetown showed that 11 per cent of the students were currently 
using cannabis, while 0.6 per cent were using cocaine and 0.4 per cent heroin.14 
Similarly, in another survey conducted among street children and youth  
aged 8-24 years, two thirds of the respondents were using cannabis, while 6.8 per 
cent were using cocaine and 5.6 per cent using heroin. The other substances of note 
__________________ 
 12  Annual report questionnaire replies submitted by Nigeria for 2010. 
 13  Given the forensic capacity in African States to properly identify substances, it is questionable 
as to the actual chemical composition of the substance referred to as cocaine, as well as other 
synthetic substances being reported from Africa. 
 14  Campaign for Development and Solidarity (FORUT), “Summary of baseline surveys on alcohol, 
drugs, cigarettes and development in Freetown” (Sierra Leone, 2011). The sample for the school 
survey included 1,245 secondary school students. 
Cannabis, 64.0%
Opioids, 18.9% Cocaine, 5.0%
Amphetamine-type 
stimulants, 5.1%
Methaqualone, 
3.7%
Sedatives and 
tranquillizers, 2.3%
Solvents and 
inhalants, 3.2%
Khat, 3.9%
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being used were diazepam, chlorpromazine and different inhalants. The study also 
revealed that 3.7 per cent of the young people had been injecting drugs.15  
24. Similarly, a survey of secondary school students conducted in Liberia showed 
that about 9 per cent of the students had used cannabis, while 0.6 per cent had used 
cocaine and 0.1 per cent had used heroin.16  
25. Increasing use of heroin and injecting drugs is also emerging as an alarming 
trend, in particular in East Africa but also in other parts of Africa, such as Kenya, 
Libya,17 Mauritius and the United Republic of Tanzania.18, 19 In sub-Saharan 
Africa, 1.78 million (range: between 535,000 and 3,022,500) drug users are 
estimated to be injecting drugs. In Kenya HIV prevalence among injecting drug 
users is estimated to be 42.9 per cent (36.3-49.5 per cent); it is 22 per cent in Libya, 
12.4 per cent in South Africa and 9.8 per cent in Mauritius.20  
26. In South Africa, trends in the use of opioids and cocaine are reported as stable, 
while some increase for cannabis use and a decrease for the use of amphetamine-
type stimulants have been reported.21 According to treatment admissions, 
methamphetamine and methcathinone are the most commonly used amphetamine-
type stimulants.  
27. There are indications that the use of amphetamine-type stimulants is also 
spreading to other areas in Africa. Their use has been reported in countries such as 
Cape Verde, Egypt, Ghana, Kenya and Nigeria. The lifetime use of amphetamines 
and Mandrax (methaqualone) in secondary schools in Nairobi is 2.6 per cent,  
with 1.6 per cent of students reporting having used them within the previous  
six months.22  
 
 
 B. Americas  
 
 
28. With an estimated 8 million cocaine users in the Americas, the use of cocaine 
remains a significant problem in the region; however, as reported by Member States, 
there are decreasing trends in the use of cocaine, while there are stable trends for the 
use of cannabis and “ecstasy”. The use of opioids and amphetamine-type stimulants, 
on the other hand, is perceived to be increasing in the region.  
 
__________________ 
 15  GOAL, “European Union substance use harm reduction programme: summary of results from 
main survey” (Sierra Leone, 2011). 
 16  Benjamin Harris and others, “Substance use behaviours of secondary school students in post-
conflict Liberia: a pilot study”, International Journal of Culture and Mental Health, 2011. 
 17  Since 16 September 2011, “Libya” has replaced “Libyan Arab Jamahiriya” as the short name 
used in the United Nations. 
 18  Chris Beyrer and others, “Time to act: a call for comprehensive responses to HIV in people who 
use drugs”, The Lancet, vol. 376, No. 9740 (14 August 2010). 
 19  Reference Group to the United Nations on HIV and Injecting Drug Use (2011 estimates). 
 20  Ibid. 
 21  Annual report questionnaire replies submitted by South Africa for 2010. 
 22  Peter Koome and National Campaign against Drug Abuse Authority (NACADA) of Kenya, 
paper on the role of school environment in alcohol and drug abuse among students: evidence 
from public secondary school students in Nairobi (see NACADA, “Promotion of evidence-based 
campaign-national alcohol and drug abuse research workshop 2011 report, annex 3). 
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 1. North America 
 
29. The non-medical use of prescription drugs remains a major problem in the 
United States, where they are reported as the second most commonly used type of 
drug after cannabis. The estimated prevalence of current cannabis use among 
persons age 12 or older in 2010 (6.9 per cent) is reported to be similar to the figure 
in 2009 (6.6 per cent) but higher than in 2008. The estimates of current non-medical 
users of prescription drugs, including opioids and stimulants, as well as of users of 
methamphetamine and “ecstasy”, also remained stable in 2010. “Ecstasy” use in 
2009 was reported to be increasing, however. While the estimated total number of 
cocaine users has remained stable since 2009, they decreased from 0.7 per cent of 
those age 12 or older in 2008 to 0.6 per cent in 2010.23  
30. In Canada, the trends for most drugs were reported as stable, while there was a 
further decline reported in past-year “ecstasy” use (from 0.9 per cent in 2009 to  
0.7 per cent in 2010).24 Salvia divinorum,25 a plant containing a psychoactive 
substance not under national control, has become a cause for concern. In 2010, an 
estimated 1.6 per cent of Canadians aged 15 years and older and 6.6 per cent of  
15-24-year-olds reported lifetime use of salvia.26  
31. For Mexico, the use of cannabis, opioids, cocaine and amphetamine-type 
stimulants is reported as declining, while stable trends have been reported for 
tranquillizers, hallucinogens and inhalants. 
32. In North America as a whole, the treatment demand for cannabis use, opioids 
and cocaine remains at levels comparable to previous years. High levels of drug-
related deaths were reported: 182.4 per million population for the United States, and 
93.34 per million population for Canada. In the United States, prescription opioids 
are the main drug type reported in drug-related deaths.  
33. In Canada and the United States, between 1.6 million and 3.1 million drug users 
are estimated to be injecting drugs, and between 127,000 and 709,000 injecting  
drug users are estimated to be living with HIV. 
 
 2. Latin America and the Caribbean 
 
34. In most of the countries in South America, cocaine use is perceived to be 
decreasing, while the use of opioids and amphetamine-type stimulants is perceived 
to be increasing, especially in Ecuador, El Salvador and Guatemala. Concern over 
rising levels of use of synthetic drugs such as “ecstasy” among South American 
youth continues to grow, and the use of pharmaceutical preparations containing 
stimulant substances is widespread in the region.27 Several countries, including 
__________________ 
 23  United States of America, Department of Health and Human Services, Substance Abuse and 
Mental Health Services Administration, “Results from the 2010 national survey on drug use and 
health: summary of national findings” (September 2011). 
 24  Annual report questionnaire replies submitted by Canada for 2009 and 2010; and Health 
Canada, “Canadian alcohol and drug use monitoring survey, summary of results for 2010”. 
 25  The primary active ingredient of Salvia divinorum is the terpenoid salvinorin A, originally 
called divinorin A. It has been described as the “most potent naturally-occurring psychedelic 
ever discovered”, being active in doses as small as 100-200 micrograms. 
 26  Health Canada, “Canadian alcohol and drug use monitoring survey, summary of results for 
2010”. 
 27  Amphetamines and Ecstasy (see footnote 3). 
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Argentina, Brazil, El Salvador, Peru and Uruguay, have also reported the use of 
ketamine. 
35. By contrast, experts in Brazil report the use of cannabis, tranquillizers and 
amphetamine-type stimulants to be decreasing, with an increase in the use of 
cocaine, especially in the smoking of crack and pasta base.28 Also, a study released 
by the National Anti-Drug Secretariat (SENAD) of Brazil in 2010 found a decrease 
in the use of amphetamine-group substances among students, from 3.2 per cent  
in 2004 to 1.6 per cent in 2010.29  
36. Cocaine, which accounts for 47.9 per cent of treatment demand, remains the 
primary substance of abuse among those treated in Latin America and the 
Caribbean, followed by cannabis (38.7 per cent). There is little reporting of 
amphetamine-type stimulants in treatment demand in the region. 
37. The region experienced relatively few drug-related deaths (2,965 deaths, or  
2 per cent of the global total), with a mortality rate (10 deaths per million 
population aged 15-64) well below the global average. The region is unique, 
however, in that countries consistently rank cocaine first and cannabis second as the 
primary cause of drug-related deaths. 
 
 
 C. Asia  
 
 
38. The drug problem in Asia’s different subregions continues to be quite distinct 
from other regions, opioids being the primary drug of concern in South-West and 
Central Asia, methamphetamine and opioids in East and South-East Asia and 
amphetamine in the Near and Middle East. Overall, most countries in Asia consider 
the use of cannabis and amphetamine-type stimulants to be increasing, while the use 
of opioids and “ecstasy” is perceived to be stable. A similar situation has been 
observed with respect to treatment demand, with a steady increase in treatment for 
use of amphetamine-type stimulants, especially in East and South-East Asia, as 
compared with opioid use.  
 
 1. East and South-East Asia 
 
39. In East and South-East Asia, the reported use of methamphetamine, especially 
crystalline methamphetamine, has become quite widespread. Crystalline 
methamphetamine is now the most commonly used drug in Brunei Darussalam, 
Indonesia, Japan, the Philippines and the Republic of Korea. Treatment demand for 
crystalline methamphetamine has also expanded considerably. In Thailand, for 
instance, there has been a 250 per cent increase in the number of people treated for 
dependence on crystalline methamphetamine over the past year.30  
__________________ 
 28  Annual report questionnaire replies submitted by Brazil for 2010. 
 29  United Nations Office on Drugs and Crime, Global Synthetics Monitoring: Analyses, Reporting 
and Trends (SMART) Programme, “Amphetamine-type stimulants in Latin America: preliminary 
assessment report 2011”. 
 30  United Nations Office on Drugs and Crime, Global Synthetics Monitoring: Analyses, Reporting 
and Trends (SMART) Programme, “Patterns and Trends of Amphetamine-Type Stimulants and 
Other Drugs: Asia and the Pacific, 2011 (November 2011). 
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40. In China, opioids are ranked as the primary drug of concern, followed by 
amphetamine-type stimulants and tranquillizers. China has also reported increasing 
numbers of users of amphetamine-type stimulants, who accounted for 55 per cent of 
newly identified drug users in 2010. Ketamine use is also reported to have increased 
in 2010 in China; Hong Kong, China; Malaysia and Viet Nam.31  
41. Injecting drug use is also an increasing concern in East and South-East Asia, 
with an estimated 3.9 million (range 3,043,500-4,913,000) drug users injecting mostly 
opioids and methamphetamine. An estimated 661,000 (range 313,333-1,251,500) 
injecting drug users are living with HIV. The countries in the subregion with the 
highest prevalence of HIV among injecting drug users are Myanmar (42.6 per cent), 
Indonesia (42.5 per cent), Viet Nam (33.85 per cent), Cambodia (22.8 per cent) and 
China (12.3 per cent).  
 
 2. Central and South-West Asia 
 
42. Opioids remain the primary drug of concern in Central and South-West Asia, 
with most countries reporting stabilizing or decreasing trends of opioid use. 
Nevertheless, many countries in the subregion, such as Georgia, Kazakhstan, 
Tajikistan and Uzbekistan, have reported increasing trends of cannabis use over the 
past year, while Georgia has also reported an increasing trend of use of 
amphetamine-type stimulants. With increasing reports of manufacturing and 
seizures of methamphetamine in some parts of Central and South-West Asia, it is 
speculated that the use of amphetamine-type stimulants is likely to emerge in the 
subregion. 
43. In many countries in Central and South-West Asia, the prevalence of HIV 
infection among injecting drug users is high, Pakistan (21 per cent), the Islamic 
Republic of Iran (15 per cent), and Uzbekistan (15.6 per cent) having the highest 
proportion of injecting drug users living with HIV.32  
 
 3. South Asia 
 
44. Among countries in South Asia, Bhutan and Sri Lanka reported a stable trend 
or decrease in the use of opioids and an increase in the use of cannabis and 
amphetamine-type stimulants, respectively. In Bangladesh the use of amphetamine-
type stimulants, especially in urban areas, has become quite widespread, with 
methamphetamine tablets widely available. In terms of treatment demand, opioids 
remain the primary drug for which the majority of drug users were treated in the 
subregion.  
 
 4. Near and Middle East 
 
45. Increased use of synthetic and prescription drugs has been reported in a 
number of countries in the Near and Middle East. For many countries in the 
subregion, opioids remain the primary drug reported in treatment; however, 
substantial demand for treatment for the use of amphetamine-type stimulants, 
cannabis and sedative and tranquillizers is also reported. 
 
 
__________________ 
 31  Ibid. 
 32  Reference Group to the United Nations on HIV and Injecting Drug Use (2011). 
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 D. Europe  
 
 
46. Cannabis remains the most commonly used controlled substance in Europe, 
followed by cocaine, amphetamine-type stimulants and opioids. For most parts of 
Europe, there are stable or declining trends reported in the use of opioids, cannabis, 
cocaine and amphetamine-type stimulants. Nevertheless, opioids and cocaine are the 
two most problematic drugs in the region. Opioids are cited as the main substances 
reported as the primary drug of abuse in treatment, as well as a major cause of  
drug-related deaths. The rapid emergence of new synthetic drugs and the increasing 
interplay between “legal highs” and illicit drug markets pose a major challenge in 
the region. An increase in new HIV infections among injecting drug users has been 
reported in Bulgaria, Estonia, Greece (traditionally a country with a low prevalence 
of HIV infection) and Lithuania. Other countries in the region with high HIV-
prevalence rates include Latvia, Portugal, the Russian Federation and Ukraine. In 
the past few years, many European countries have reported declining availability of 
“ecstasy”; however, most recent reports indicate a possible resurgence and 
increasing purity of “ecstasy” in Europe.  
 
 1. Western and Central Europe 
 
47. The recent data in Europe indicate a stabilizing or decreasing trend in cannabis 
use, especially among young adults (aged 15-34 years). This decline in cannabis use 
may in part be influenced by the declining rate of tobacco smoking among young 
people. Changes in lifestyle, fashion, replacement with other drugs and perceptions 
about cannabis use could also explain this trend.33  
48. In the past decade, cocaine established itself as the most commonly used 
stimulant in Europe, although most of the cocaine users were in Western European 
countries. Recent surveys indicate some decline in the past year in the use of 
cocaine among young adults in high-prevalence countries: Denmark, Italy, Spain 
and the United Kingdom. Nevertheless, cocaine accounted for 17 per cent of 
treatment demand and about 1,000 drug-related deaths in the region.34  
49. The latest data also show stable trends in the use of opioids. Nevertheless, 
opioid users account for nearly half of the treatment demand, although they 
represent an older cohort and fewer of them inject heroin. The majority of the  
7,600 drug-related deaths in the region were attributed to opioid use. Despite heroin 
being the main opioid used, there are reports that synthetic opioids such as fentanyl 
and buprenorphine might have displaced it in some countries, notably in Estonia and 
Finland.  
50. There remains a significant level of amphetamine use in the region. While 
methamphetamine use had earlier remained restricted to the Czech Republic and 
Slovakia, there are recent reports of its increased availability in Latvia, Norway and 
Sweden; in those countries, its use is thought to be replacing that of amphetamine.35  
 
__________________ 
 33  The State of the Drugs Problem in Europe (see footnote 8). 
 34  Ibid. 
 35  Ibid. 
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 2. Eastern and South-Eastern Europe 
 
51. In Eastern and South-Eastern Europe, many countries have reported an 
increasing trend in the use of cannabis and amphetamine-type stimulants, including 
“ecstasy”, while the use of opioids and cocaine is reported as stable. Nevertheless, 
opioids, mainly heroin, remain the main problematic drug in the subregion, 
representing 68 per cent of the treatment demand and a major cause of drug-related 
deaths.  
52. In the past decade, Eastern Europe (and Central Asia) have experienced a rapid 
rise in HIV infections, which has been driven primarily by the interplay between 
injecting drug use and sex work.36 Between 39 and 50 per cent of injecting drug 
users in Ukraine and more than a third of injecting drug users in the Russian 
Federation are estimated to be living with HIV.37, 38  
53. In the Russian Federation, stable trends are reported for the use of opioids and 
amphetamine-type stimulants, while there has been a decrease in the use of cannabis 
and cocaine.39 As reported by the Russian authorities, while there has been a 
shortage of heroin, this has reportedly been substituted by the use of desomorphine, 
acetylated opium and, in some regions, fentanyl.40 Among the 9,263 drug-related 
deaths, 6,324 were reported to be among opioid users. 
 
 
 E. Oceania 
 
 
54. The information from Oceania primarily represents the drug situation as 
reported by Australia and New Zealand, since the small Pacific island States do not 
respond to the annual report questionnaire.  
55. In Australia, an increase in cocaine and cannabis use has been reported, while 
the use of opioids is considered to be stable and that of amphetamine-type 
stimulants — methamphetamine, amphetamine and “ecstasy” — to have decreased. 
Cannabis remains the most prevalent drug in Australia, as well as the major illicit 
substance reported in treatment demand (representing 50 per cent of cases), while 
nearly 20 per cent of the treatment demand is for heroin and amphetamine use.41 Of 
the 1,790 drug-related deaths in Australia, nearly 40 per cent were the result of 
opioids and around a quarter attributed to benzodiazepines. 
56. In New Zealand, while stable trends are reported for the use of most drugs, 
there is some increase reported in the use of prescription opioids and stimulants and 
benzodiazepines. A large decrease in the use of “ecstasy” has been offset by the use 
__________________ 
 36  Joint United Nations Programme on HIV/AIDS (UNAIDS), Global Report: UNAIDS Report on 
the Global AIDS Epidemic 2010. 
 37  Ibid. 
 38  By contrast, the Federal Drug Control Services of the Russian Federation reported a 14.4 per 
cent HIV prevalence among registered injecting drug users on its annual report questionnaire  
for 2010. 
 39  Annual report questionnaire replies submitted by the Russian Federation for 2010. 
 40  Ibid. 
 41  Annual report questionnaire replies submitted by Australia for 2010. 
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of other substances that mimic their effects, including many piperazines, cathinone 
and mephedrone.42, 43 
57. In the Pacific island States, there is sketchy information available on the extent 
of drug use; however, the use of kava (Piper methysticum) and cannabis is 
considered to be quite common and widespread. The use of amphetamine-type 
stimulants among secondary school students is now also reported in many Pacific 
island States, with high lifetime prevalence rates of methamphetamine use reported 
in the Marshall Islands and Palau. There is also evidence of use of 
methamphetamine by injection on many Pacific islands.30 
 
 
 III. Promoting rehabilitation- and reintegration-oriented 
strategies in response to drug use disorders and their 
consequences 
 
 
58. The report of the Executive Director on action taken by Member States to 
implement the Political Declaration and Plan of Action on International Cooperation 
towards an Integrated and Balanced Strategy to Counter the World Drug Problem 
(E/CN.7/2012/14) contains an analysis of the responses of Member States with 
regard to drug treatment and care policies and programmes aimed at rehabilitation 
and reintegration. 
59. In addition, UNODC undertook a number of activities in 2011, pursuant to 
Commission on Narcotic Drugs resolution 54/5. The Office continued to promote 
and support, jointly with the World Health Organization, a worldwide response to 
ensure evidence-based and ethical treatment policies, strategies and interventions 
aimed at the rehabilitation and reintegration of drug-dependent people. 
60. UNODC supported the implementation of a global strategy for knowledge 
dissemination, contributing significantly to the transfer of skills and good practices 
through training on evidence-based methodologies in the field of treatment of drug 
dependence that are aimed at rehabilitation and reintegration, spreading good 
clinical practice and promoting high-quality clinical standards among services 
providing treatment for drug dependence in more than 25 countries. The strategy 
has contributed to building bridges between research evidence and treatment 
policies and practices that promote health and social well-being among individuals, 
families and communities. 
61. Moreover, UNODC supported treatment interventions in 30 countries (see map 4) 
that were aimed at increasing the availability of treatment, rehabilitation and 
reintegration facilities in order to reach those in need, including the most 
marginalized, by promoting a client-oriented continuum of care approach that is 
mainstreamed into the health-care system. Interventions encouraged participation 
and coordination between different sectors (health, social welfare, criminal justice 
and law enforcement) and an appropriate balance between specialized services and 
primary care. They contributed to a comprehensive treatment system aimed at 
rehabilitation and reintegration, with services provided at a variety of levels and 
integrated care across different health and welfare services, outreach and clinical 
__________________ 
 42  4-methylethcathinone, TFMPP, BZP. 
 43  Annual report questionnaire replies submitted by New Zealand for 2010. 
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settings, outpatient and residential facilities, and treatment and rehabilitation 
centres. This approach allowed services to be available, accessible and affordable, 
hence making it possible for drug users, families and communities to attend 
treatment programmes. This multidisciplinary approach will ultimately lead to 
rehabilitating and reintegrating persons affected by drug use and dependence into 
society. 
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62. Standards of care in treatment for drug dependence were developed to guide 
and assist Member States in their efforts to develop programmes and appropriate 
treatment services based on scientific and research-based evidence.  
63. In addition, UNODC has launched a global initiative to promote a worldwide 
coordinated response of public institutions and non-governmental organizations to 
children and adolescents at risk and/or those affected by drug use, drug dependence 
and its health and social consequences. The initiative is aimed at preventing drug 
abuse, treating drug dependence and facilitating the integration of former drug 
abusers into society. The initiative includes a large-scale mobilization, with the 
involvement of civil society, academics, media and high-ranking personalities. It 
calls for immediate action to improve the living conditions of children worldwide, 
reduce the risks of developing drug use disorders and provide appropriate treatment 
strategies tailored to the specific needs of this age group. UNODC has developed 
scientifically based, specialized protocols for the treatment (both psychosocial and 
pharmacological) of drug use disorders among children, as well as a capacity-
building component which will target clinical and educational service providers 
from various disciplines working at various levels and in various settings. 
 
 
 IV. Conclusions and recommendations 
 
 
64. In recent years, there has not been a significant increase in the estimated 
number of illicit drug users in the world. There are stabilizing or decreasing trends 
in the use of traditional, or conventional, drugs of abuse, such as cocaine and 
heroin, which are especially evident in North America and Europe. The stabilizing 
trends are offset, however, by the increasing use of those drugs reported in parts of 
Africa and Asia. In many regions, the introduction of new synthetic substances and 
substitution by prescription drugs, as well as by substances not under international 
control, are also emerging as major challenges. Similarly, the phenomenon of 
polydrug use obliterates the distinction between users of different substances, both 
internationally controlled substances and substances not under international control. 
All of these trends need to be monitored and further explored. 
65. Opioids continue to pose a major public health concern — in terms of the 
higher proportion of opioid users who are injecting opioid users and infected with 
HIV, and in terms of their attribution as a major cause of drug-related deaths. HIV 
infections and drug-related deaths are conditions that can still be prevented by the 
introduction of evidence-based services for HIV prevention, overdose prevention, 
treatment and care. Surveillance of injecting drug users, the monitoring of HIV 
infections among at-risk populations and the reporting of drug-related deaths need 
to be further improved to realistically capture the trends.  
66. There remains a major gap, as well as an unmet need, in the provision of 
evidence-based interventions for the treatment and care of drug-dependent persons 
and those with drug use disorders globally. This is more marked for Asia and Africa, 
particularly in countries that have a high prevalence and also a high proportion of 
drug users that are in urgent need of these interventions. Coverage of services and 
treatment reporting in many developed and developing countries therefore need to 
be strengthened. 
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67. There continues to be a need to explore the various interacting factors that may 
have resulted in stabilizing trends in the use of certain drugs, as well as the 
emerging trends with respect to other drugs.  
68. In order to capture and report the emergence of new synthetic substances and 
trends in drug use in different parts of the world, there is a need to develop 
guidelines for implementing early warning and reporting systems to monitor these 
new and emerging trends. Mechanisms also need to be identified by which 
information on emerging trends and drug use patterns could be shared among 
experts in regional and international forums. 
69. Objective and current information on drug use patterns and trends is  
non-existent in many developing countries. Most countries lack any systematic 
monitoring and collection of data through the key epidemiological indicators of 
drug use. There is a lack of data on drug use trends in major subregions such as 
West and Central Africa, South Asia, South-West and Central Asia and parts of East 
Asia, the Caribbean and parts of Latin America and Pacific island States. There is 
evidence that countries that have improved their capacity to monitor their drug use 
situation, i.e. that have invested resources in instituting drug use monitoring 
systems, have also been better poised to tackle their drug problems with 
interventions that are informed by evidence and with the efficient use of resources. 
Despite the best intentions of Member States, this remains a missing link in 
developing and implementing evidence-informed policies for the reduction of illicit 
demand for drugs. 
70. As a meaningful response to demand-reduction efforts, Member States need to 
support UNODC in assisting other Member States in increasing their capacity to 
monitor the drug use situation through the systematic development of national drug 
observatories. 
 
